论文部分内容阅读
1例71岁男性患者因高血压病、冠状动脉粥样硬化性心脏病给予注射用血塞通800 mg加入0.9%氯化钠注射液250 ml静脉滴注、1次/d。用药前肝功能正常。用药第3天，患者出现食欲不振、上腹部不适和皮疹，实验室检查示血清丙氨酸转氨酶（ALT）490 U/L，天冬氨酸转氨酶（AST）657 U/L，总胆红素（TBil）33.4 μmol/L，直接胆红素（DBil）10.3 μmol/L，碱性磷酸酶（ALP）51 U/L。次日出现黄疸，ALT 2 597 U/L，AST 2 647 U/L，TBil 74.6 μmol/L，DBil 24.3 μmol/L，ALP 58 U/L，凝血酶原活动度（PTA）20%，国际标准化比值2.4。诊断为严重肝损伤，考虑可能与注射用血塞通相关。停用该药，给予多烯磷脂酰胆碱注射液和异甘草酸镁注射液保肝治疗。1周后患者ALT 785 U/L，AST 653 U/L，TBil 46.0 μmol/L，ALP 44 U/L，PTA 42%。7 d后随访，患者皮疹消退，ALT 433 U/L，AST 372 U/L，TBil 35.2 μmol/L，DBil 10.1 μmol/L，ALP 48 U/L。“,”A 71-year-old male patient, who was admitted to hospital for hypertension and coronary artery heart disease, received an IV infusion of n Xuesaitong for injection 800 mg dissolved in 250 ml of 0.9% sodium chloride injection once daily. His liver function was normal before treatment. On day 3 of treatment, the patient developed anorexia, epigastric discomfort, and rash. Laboratory tests showed that the alanine aminotransferase (ALT) was 490 U/L, aspartate aminotransferase (AST) was 657 U/L, total bilirubin (TBil) was 33.4 μmol/L, direct bilirubin (DBil) was 10.3 μmol/L, and alkaline phosphatase (ALP) was 51 U/L. The next day, the patient developed jaundice. The laboratory tests showed ALT 2 597 U/L, AST 2 647 U/L, TBil 74.6 μmol/L, DBil 24.3 μmol/L, ALP 58 U/L, prothrombin activity (PTA) 20%, and international normalized ratio 2.4. It was diagnosed as severe liver injury and was related to n Xuesaitong for injection. The drug was stopped and liver-protective treatments such as polyene phosphatidylcholine injection and isoglycyrrhizic acid magnesium injection were given. One week later, the patients′ liver function improved (ALT 785 U/L, AST 653 U/L, TBil 46.0 μmol/L, ALP 44 U/L, and PTA 42%). He was transferred to another hospital. At 7 days of follow-up, the rash disappeared and laboratory tests showed ALT 433 U/L, AST 372 U/L, TBIL 35.2 μmol/L, DBIL 10.1 μmol/L, and ALP 48 U/L. No follow-up was continued after then.n